Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC)

Radiotherapy and Oncology

Volumn 102, Issue 2, 2012, Pages 251-257

  Edet Sanson, Agathe ^a   Dubray, Bernard ^a   Doyeux, Kaya ^a   Back, Adeline ^a   Hapdey, Sebastien ^a   Modzelewski, Romain ^a   Bohn, Pierre ^a   Gardin, Isabelle ^a   Vera, Pierre ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

FDG; Lung cancer; PET CT; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; ARTIFACT; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RADIOACTIVITY; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 84857624207     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.07.023     Document Type: Article

References (33)

1. D. De Ruysscher, and C.M. Kirsch PET scans in radiotherapy planning of lung cancer Radiother Oncol 96 2010 335 338
2. V. Gregoire, and A. Chiti PET in radiotherapy planning: particularly exquisite test or pending and experimental tool? Radiother Oncol 96 2010 275 276
3. Y.E. Erdi, H. Macapinlac, K.E. Rosenzweig, J.L. Humm, S.M. Larson, and A.K. Erdi Use of PET to monitor the response of lung cancer to radiation treatment Eur J Nucl Med 27 2000 861 866
4. F.M. Kong, K.A. Frey, L.E. Quint, R.K. Ten Haken, J.A. Hayman, and M. Kessler A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer J Clin Oncol 25 2007 3116 3123
5. A. van Baardwijk, G. Bosmans, A. Dekker, K.M. van KM, L. Boersma, and S. Wanders Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients Radiother Oncol 82 2007 145 152
6. H.J. Aerts, A.A. van Baardwijk, S.F. Petit, C. Offermann, J. Loon, and R. Houben Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan Radiother Oncol 91 2009 386 392
7. L. Decoster, D. Schallier, H. Everaert, K. Nieboer, M. Meysman, and B. Neyns Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC) Lung Cancer 62 2008 55 61
8. D. Hellwig, R.P. Baum, and C. Kirsch FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review Nuklearmedizin 48 2009 59 69
9. C.J. Hoekstra, S.G. Stroobants, E.F. Smit, J. Vansteenkiste, T.H. van, and P.E. Postmus Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer J Clin Oncol 23 2005 8362 8370
10. W. Huang, T. Zhou, L. Ma, H. Sun, H. Gong, and J. Wang Standard uptake value and metabolic tumor volume of (18)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer Eur J Nucl Med Mol Imaging 38 2011 1628 1635
11. C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, and R. Pink Value of 18F-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy Clin Cancer Res 12 2006 97 106
12. H.Q. Zhang, J.M. Yu, X. Meng, J.B. Yue, R. Feng, and L. Ma Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy Eur J Radiol 77 2011 92 96
13. J.F. Daisne, M. Sibomana, A. Bol, T. Doumont, M. Lonneux, and V. Gregoire Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms Radiother Oncol 69 2003 247 250
14. S. Vauclin, K. Doyeux, S. Hapdey, A. Edet-Sanson, P. Vera, and I. Gardin Development of a generic thresholding algorithm for the delineation of 18FDG-PET-positive tissue: application to the comparison of three thresholding models Phys Med Biol 54 2009 6901 6916
15. C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, and J. Dupuis Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis J Nucl Med 48 2007 1626 1632
16. P. Giraud, M. Antoine, A. Larrouy, B. Milleron, P. Callard, and Y. De Rycke Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning Int J Radiat Oncol Biol Phys 48 2000 1015 1024
17. O. Chapet, F.M. Kong, L.E. Quint, A.C. Chang, R.K. Ten Haken, and A. Eisbruch CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan Int J Radiat Oncol Biol Phys 63 2005 170 178
18. P. Giraud, R.Y. De, A. Lavole, B. Milleron, J.M. Cosset, and K.E. Rosenzweig Probability of mediastinal involvement in non-small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy? Int J Radiat Oncol Biol Phys 64 2006 127 135
19. Y.E. Erdi, O. Mawlawi, S.M. Larson, M. Imbriaco, H. Yeung, and R. Finn Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding Cancer 80 1997 2505 2509
20. Q.C. Black, I.S. Grills, L.L. Kestin, C.Y. Wong, J.W. Wong, and A.A. Martinez Defining a radiotherapy target with positron emission tomography Int J Radiat Oncol Biol Phys 60 2004 1272 1282
21. U. Nestle, S. Kremp, A. Schaefer-Schuler, C. Sebastian-Welsch, D. Hellwig, and C. Rube Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer J Nucl Med 46 2005 1342 1348
22. K. Wu, Y.C. Ung, D. Hwang, M.S. Tsao, G. Darling, and D.E. Maziak Autocontouring and manual contouring: which is the better method for target delineation using 18F-FDG PET/CT in non-small cell lung cancer? J Nucl Med 51 2010 1517 1523
23. G. Storto, E. Nicolai, and M. Salvatore [18F]FDG-PET-CT for early monitoring of tumor response: when and why Q J Nucl Med Mol Imaging 53 2009 167 180
24. T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, and M. Hutchings Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review J Clin Oncol 27 2009 1906 1914
25. M. Hutchings, and S.F. Barrington PET/CT for therapy response assessment in lymphoma J Nucl Med 50 2009 21S 30S
26. X. Geets, J.F. Daisne, M. Tomsej, T. Duprez, M. Lonneux, and V. Gregoire Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies Radiother Oncol 78 2006 291 297
27. C. Gillham, D. Zips, F. Ponisch, C. Evers, W. Enghardt, and N. Abolmaali Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol 88 2008 335 341
28. P. Vera, P. Bohn, A. Edet-Sanson, A. Salles, S. Hapdey, and I. Gardin Simultaneous positron emission tomography (PET) assessment of metabolism with (18)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (18)F-fluoro-thymidine (FLT), and hypoxia with (18)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study Radiother Oncol 98 2011 109 116
29. M. Feng, F.M. Kong, M. Gross, S. Fernando, J.A. Hayman, and R.K. Ten Haken Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing Int J Radiat Oncol Biol Phys 73 2009 1228 1234
30. M. Okubo, Y. Nishimura, K. Nakamatsu, M. Okumura, T. Shibata, and S. Kanamori Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancers: a multiple-threshold method for [(18)F]fluoro-2-deoxyglucose activity Int J Radiat Oncol Biol Phys 77 2010 350 356
31. M. Wanet, J.A. Lee, B. Weynand, M. De Bast, A. Poncelet, and V. Lacroix Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens Radiother Oncol 98 2011 117 125
32. A. Auperin, P.C. Le, J.P. Pignon, C. Koning, B. Jeremic, and G. Clamon Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients Ann Oncol 17 2006 473 483
33. A. van Baardwijk, C. Dooms, R.J. van Suylen, E. Verbeken, M. Hochstenbag, and C. Hing-Oberije The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer Eur J Cancer 43 2007 1392 1398